CannaPharmaRx Inc
CannaPharmaRX, Inc. engages in acquisition, development, and operation of cannabis cultivation facilities in Canada. It produces and sells dried cannabis flower. The company is based in Calgary, Canada.
CannaPharmaRx Inc (CPMD) - Net Assets
Latest net assets as of September 2025: $-22.52 Million USD
Based on the latest financial reports, CannaPharmaRx Inc (CPMD) has net assets worth $-22.52 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.62 Million) and total liabilities ($34.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-22.52 Million |
| % of Total Assets | -193.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 241.29 |
CannaPharmaRx Inc - Net Assets Trend (1998–2024)
This chart illustrates how CannaPharmaRx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CannaPharmaRx Inc (1998–2024)
The table below shows the annual net assets of CannaPharmaRx Inc from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-19.81 Million | -63.00% |
| 2023-12-31 | $-12.15 Million | +29.93% |
| 2022-12-31 | $-17.34 Million | -34.18% |
| 2021-12-31 | $-12.93 Million | -46.86% |
| 2020-12-31 | $-8.80 Million | -281.32% |
| 2019-12-31 | $4.85 Million | +726.91% |
| 2018-12-31 | $-774.30K | +19.70% |
| 2017-12-31 | $-964.30K | -0.69% |
| 2016-12-31 | $-957.67K | -39.90% |
| 2015-12-31 | $-684.54K | -137.50% |
| 2014-12-31 | $-288.23K | -45.84% |
| 2012-12-31 | $-197.63K | -98.50% |
| 2011-12-31 | $-99.56K | +82.98% |
| 2007-12-31 | $-585.00K | +92.64% |
| 2006-12-31 | $-7.95 Million | -210.82% |
| 1999-12-31 | $7.17 Million | +262.12% |
| 1998-12-31 | $1.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CannaPharmaRx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10114414200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $66.25K | % |
| Other Comprehensive Income | $555.63K | % |
| Other Components | $80.75 Million | % |
| Total Equity | $-19.81 Million | 100.00% |
CannaPharmaRx Inc Competitors by Market Cap
The table below lists competitors of CannaPharmaRx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
|
$2.39 Million |
|
Pearl Gull Iron Ltd
AU:PLG
|
$2.39 Million |
|
Lilium N.V.
PINK:LILWF
|
$2.39 Million |
|
PT Hetzer Medical Indonesia Tb
JK:MEDS
|
$2.39 Million |
|
OSI SYSTEMS
MU:OS2
|
$2.38 Million |
|
AIR PROD.&CHEMICALS
MU:AP3
|
$2.38 Million |
|
Menteng Heritage Realty Tbk PT
JK:HRME
|
$2.38 Million |
|
Park & Bellheimer AG
F:PKB
|
$2.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CannaPharmaRx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -12,153,213 to -19,809,637, a change of -7,656,424.
- Net loss of 9,906,000 reduced equity.
- Other comprehensive income increased equity by 591,243.
- Other factors increased equity by 1,658,333.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.91 Million | -50.01% |
| Other Comprehensive Income | $591.24K | +2.98% |
| Other Changes | $1.66 Million | +8.37% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CannaPharmaRx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.01 | $0.00 | x |
| 1999-12-31 | $2.33 | $0.00 | x |
| 2006-12-31 | $-3.12 | $0.00 | x |
| 2007-12-31 | $-0.28 | $0.00 | x |
| 2008-12-31 | $-0.30 | $0.00 | x |
| 2009-12-31 | $-0.24 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $-0.04 | $0.00 | x |
| 2012-12-31 | $-0.08 | $0.00 | x |
| 2013-12-31 | $-0.12 | $0.00 | x |
| 2014-12-31 | $-0.03 | $0.00 | x |
| 2017-12-31 | $-0.05 | $0.00 | x |
| 2018-12-31 | $-0.05 | $0.00 | x |
| 2019-12-31 | $0.16 | $0.00 | x |
| 2020-12-31 | $-0.22 | $0.00 | x |
| 2021-12-31 | $-0.17 | $0.00 | x |
| 2022-12-31 | $-0.06 | $0.00 | x |
| 2023-12-31 | $-0.04 | $0.00 | x |
| 2024-12-31 | $-0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CannaPharmaRx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1207.85%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (27376.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -2.01% | 0.00% | 0.00x | 1.14x | $-239.00K |
| 1999 | -66.25% | -766.13% | 0.06x | 1.34x | $-5.47 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $804.20K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $7.17 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-133.07K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $166.49K |
| 2010 | 575404.00% | 0.00% | 0.00x | 1.00x | $575.39K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-89.70K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-78.30K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.20K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.95 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.67 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-905.48K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $89.80K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.00 Million |
| 2019 | -421.31% | 0.00% | 0.00x | 3.30x | $-20.94 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.01 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.54 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.80 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $4.90 Million |
| 2024 | 0.00% | -1207.85% | 0.08x | 0.00x | $-7.93 Million |
Industry Comparison
This section compares CannaPharmaRx Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CannaPharmaRx Inc (CPMD) | $-22.52 Million | -2.01% | N/A | $2.39 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |